FSTL3 and metabolic dysfunction-associated steatotic liver disease: The purposes of this study are as follows: firstly, to investigate the association of NAFLD and its fibrosis risk with occurrence and severity of AMI in patients with T2DM; and secondly, to determine the mediating role of serum FSTL3 in the association of increased NAFLD fibrosis risk with occurrence and severity of AMI.